Refine by
Drug Eluting Articles & Analysis
39 news found
Next came Ocular Therapeutix Inc., to develop an absorbable punctal plug for the extended delivery of drugs to the surface of the eye. Augmenix Inc., now part of Boston Scientific Corp. ...
SAN DIEGO–(BUSINESS WIRE)–Today, MediPrint™ Ophthalmics, an emerging San Diego-based clinical stage eye care pharmaceutical company focused on helping protect sight, announces the acceptance and presentation of a poster highlighting its latest clinical results at the upcoming Global Specialty Lens Symposium (GSLS), a leading eye care conference. The poster spotlights the results ...
” REVA’s MOTIV device represents a unique breakthrough technology for the treatment of patients suffering from below-the-knee peripheral vascular disease. MOTIV is a drug-eluting bioresorbable peripheral vascular scaffold made from REVA’s proprietary Tyrocore polymer that is designed to dissolve over time, leaving the artery free of a permanent ...
He also spent three years on an expatriate assignment in Europe leading the launch of Medtronic’s first drug eluting coronary stent. Prior to Medtronic, he spent four years at ABN AMRO bank in Chicago focused on healthcare transactions. ...
Professor Serruys presented a talk entitled “Bench testing evaluation of a novel fully drug-eluting BRS” at EuroPCR on 19th May 2016. The talk was part of the “BRS: Evolving Technologies and Applications” session, also featuring presentations about Elixir’s DESolve scaffold, Abbott’s ABSORB clinical data, Biotronik’s ...
The trial evaluated the safety and performance of the Company’s Fantom sirolimus-eluting bioresorbable coronary scaffold in over 240 patients outside the United States. ...
With the additional secured funding, as well as the poster’s reception by a leading eye care practitioner society, MediPrint’s platform drug delivery technology has now been further validated by both the investment and the eye care professional communities. ...
Arterius has recently completed the pre-clinical trials and, on the back of these, believes that this collaboration has delivered a next generation drug eluting fully biodegradable stent. This technology is now being evaluated in this first application in human trials. ...
– February 15, 2022 – Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, today announced completion of enrollment in the BIOADAPTOR randomized controlled trial (RCT). The BIOADAPTOR RCT is evaluating the DynamX™ Coronary Bioadaptor System, the first drug-eluting coronary artery ...
The small molecule, precisely-dosed, delivered to the affected area through a proprietary drug-eluting carrier, stimulates stem cells, activating cells to grow healthy bone known as “osteoblasts”, and inhibits cells associated with bone degradation called “osteoclasts”. ...
The technology is a first-of-its kind molecular pathway designed to suspend cancer, inhibit pain, and regenerate bone Zetagen Therapeutics is developing the therapy for patients living with metastatic bone lesions and other osteologic conditions The Company is targeting its first human clinical trial for metastatic bone lesions to begin in early 2022 Zetagen Therapeutics, a private, ...
Intersect ENT’s PROPEL Contour is a drug-eluting, bioabsorbable sinus implant that is placed in the frontal sinus (between the eyebrows) following sinus surgery. ...
BONESUPPORT™, an emerging leader in orthobiologics for the management of bone injuries, today announced that the company has submitted a supplementary De Novo application to the US Food and Drug Administration (FDA) to obtain a market approval for the company’s antibiotic-releasing product CERAMENT® G. ...
Company to Initiate Phase 3 ENLIGHTEN Program around YE’21 Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues, today announced that the positive results of the Company’s Phase ...
“Our commercial efforts in driving global expansion, through expanding use of CGuard EPS in our 33 served markets, combined with growing our footprint into the U.S. and Asia, has created awareness of the clinical advantages of CGuard EPS. Initiating our U.S Food and Drug Administration (FDA) C-Guardians IDE trial this quarter marked a milestone for the company in ...
It is one of the top 10 most costly medical conditions for employers, with most patients reporting 5-15+ years of suffering and medical treatment.1-3 Intersect ENT's PROPEL implant – used primarily in hospitals and ambulatory surgery centers – is a bioabsorbable, drug-eluting implant inserted after sinus surgery to keep passageways open and deliver an ...
The new corporate logo was designed to better reflect and illustrate the purpose and passion underlying the Company’s goal to use the MediPrint process to help protect sight by printing ophthalmic drugs on the surface of contact lenses. Additionally, the new web site is www.mediprintlens.com. ...
PROPEL Contour is specifically designed to maintain patency and reduce inflammation, and conform to the sinus ostia (openings) by focusing mechanical support and steroid delivery where it is needed to optimize sinus surgery outcomes. It is the third localized drug delivery implant, completing the PROPEL family of drug-eluting, bioabsorable ...
ZetaMet™ is a synthetic, small-molecule, inductive biologic, delivered via a drug-eluting implant on an osteopromotive carrier. The European patent follows the previously issued Australian Patent. ...
– April 22, 2021 – Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, today announced that the BIOADAPTOR randomized controlled trial (RCT) is expanding to centers in Belgium and Germany. The BIOADAPTOR RCT is evaluating the DynamX™ Coronary Bioadaptor System, the first drug-eluting ...